arrow
U

Ulf Dahlström

Linköping University
H指数:69
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Type 2 diabetes and chronic kidney disease combinations in heart failure across the ejection fraction spectrum: clinical associations, medication use, and cause-specific outcomes: a contemporary, real-world analysis of the Swedish Heart Failure Registry

心力衰竭中射血分数谱范围内的2型糖尿病与慢性肾脏疾病合并情况:临床关联、药物使用和特定原因结局:一项基于瑞典心力衰竭登记系统的当代真实世界分析

2026-09-020
PRE
Impact of type 2 diabetes on the relationship between chronic kidney disease and cardiovascular outcomes in heart failure across ejection fraction: observational study from the Swedish heart failure and the Swedish National diabetes registries

2型糖尿病对射血分数不同水平的心力衰竭患者中,慢性肾脏疾病与心血管结局关系的影响:来自瑞典心力衰竭登记册和瑞典国家糖尿病登记册的观察性研究

2025-12-010
OAAI
Global patterns of polypharmacy after acute heart failure hospitalization: Prevalence and outcomes from the REPORT-HF registry

急性心力衰竭住院后的多药联用全球模式:来自REPORT-HF注册研究的患病率与结局

2025-10-011
OAAI
Characterizing Heart Failure Across the Spectrum of the Preserved Ejection Fraction: Does Heart Failure With Supranormal Ejection Fraction Exist? Data From the Swedish Heart Failure Registry

在保留的射血分数范围内表征心力衰竭: 存在超正常射血分数的心力衰竭吗?来自瑞典心力衰竭登记处的数据

2025-03-181
OAAI
The association between anemia, hospitalization, and all-cause mortality in patients with heart failure managed in primary care: An analysis of the Swedish heart failure registry

初级保健管理的心力衰竭患者的贫血,住院和全因死亡率之间的关系: 瑞典心力衰竭登记处的分析

2025-02-011
OAAI
The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design

射血分数保留的心力衰竭的螺内酯初始注册随机介入试验 (SPIRRIT-HFpEF): 原理和设计

2024-09-160
OA
Status and timing of angiotensin receptor-neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry

心力衰竭和射血分数降低患者使用血管紧张素受体-脑啡肽酶抑制剂的状态和时机: 来自瑞典心力衰竭注册中心的数据

2024-07-302
OA
Sex differences in the prognostic role of achieving target doses of heart failure medications: Data from the Swedish Heart Failure Registry

达到目标剂量的心力衰竭药物的预后作用中的性别差异: 来自瑞典心力衰竭登记处的数据

2024-05-022
OA
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries
2024-04-170
OAAI